21 April, 2025 in Investor Relations Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
14 April, 2025 in Investor Relations Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
02 April, 2025 in Investor Relations Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
26 March, 2025 in Investor Relations Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
03 March, 2025 in Investor Relations Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
28 February, 2025 in Investor Relations Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
26 February, 2025 in Investor Relations Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
10 February, 2025 in Investor Relations Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
03 February, 2025 in Investor Relations Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
23 January, 2025 in Investor Relations Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23
